90.78

9.10% 7.575

Tarsus Pharmaceuticals Inc (TARS)

Overview News Price History Option Chain Financials Discussions Forecast

Tarsus Pharmaceuticals Inc stock is traded at $90.78, with a volume of 1.60M. It is up +9.10% in the last 24 hours and up +48.55% over the past month. Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.

Previous Close:

$83.20

Open:

$82.7

24h Volume:

1.60M

Relative Volume:

1.70

Market Cap:

$3.98B

Revenue:

$535.08M

Net Income/Loss:

$-48.27M

P/E Ratio:

-80.09

EPS:

-1.1335

Net Cash Flow:

$-31.54M

1W Performance:

+26.51%

1M Performance:

+48.55%

6M Performance:

+19.13%

1Y Performance:

+58.07%

1-Day Range:

$81.07

$91.53

1-Week Range:

$70.71

$91.53

52-Week Range:

$48.20

$91.53

Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile

Name

Tarsus Pharmaceuticals Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

(949) 409-9820

Address

15440 LAGUNA CANYON ROAD, IRVINE

Employee

370

Twitter

Next Earnings Date

2026-08-05

Latest SEC Filings

TARS's Discussions on Twitter

Compare TARS vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TARS Tarsus Pharmaceuticals Inc	90.78	3.14B	535.08M	-48.27M	-31.54M	-1.1335
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-24-26	Resumed	Oppenheimer	Outperform
Dec-09-25	Initiated	Barclays	Overweight
Nov-20-25	Initiated	Mizuho	Outperform
Jun-02-25	Resumed	Oppenheimer	Outperform
May-27-25	Resumed	H.C. Wainwright	Buy
Nov-20-23	Initiated	Goldman	Neutral
Jul-18-23	Initiated	William Blair	Outperform
May-18-23	Initiated	Guggenheim	Buy
Aug-01-22	Initiated	Barclays	Overweight
Dec-21-21	Initiated	H.C. Wainwright	Buy
Nov-23-21	Initiated	Oppenheimer	Outperform
Nov-10-20	Initiated	BofA Securities	Buy
Nov-10-20	Initiated	Jefferies	Buy
Nov-10-20	Initiated	Ladenburg Thalmann	Buy
Nov-10-20	Initiated	Raymond James	Strong Buy

View All

Tarsus Pharmaceuticals Inc Stock (TARS) Latest News

Aug 21, 2026

Tarsus (TARS) Technicals: Finishes 1.69% Up at $72.70 in the Latest Session; Next Test: Support at $69.06 and Resistance at $76.34 Frame the Range in Latest TradingVWAP Bounce - vinanet.vn

Aug 21, 2026

Aug 19, 2026

Tarsus (NASDAQ: TARS) ex-officer plans sale of 53K shares - Stock Titan

Aug 19, 2026

Aug 18, 2026

TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay Scheme - Stocktwits

Aug 18, 2026

Midday Stock Roundup: Eledon Falls 3.5% - Orange County Business Journal

Aug 18, 2026

TimesSquare Capital Management LLC Takes $23.25 Million Position in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat

Aug 18, 2026

Aug 17, 2026

Why Tarsus Pharmaceuticals (TARS) Is Up 6.8% After Raising XDEMVY 2026 Sales GuidanceAnd What's Next - Sahm

Aug 17, 2026

Tarsus Pharmaceuticals (TARS) Shares Just Moved, What Is Behind The Attention? - Sahm

Aug 17, 2026

Aug 16, 2026

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Aug 16, 2026

Aug 14, 2026

Q2 2026 Tarsus Pharmaceuticals, Inc. Earnings Call Transcript - GuruFocus

Aug 14, 2026

Aug 13, 2026

Tarsus Pharmaceuticals (TARS) Stock Looks Reasonable On Sales While Earnings Stay Weak - Yahoo Finance

Aug 13, 2026

William Blair Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating - Moomoo

Aug 13, 2026

Janus Henderson Group Ltd. (TARS) discloses 6.5% beneficial stake in Tarsus - Stock Titan

Aug 13, 2026

Wasatch Advisors LP Buys New Holdings in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat

Aug 13, 2026

How (TARS) Movements Inform Risk Allocation Models - Stock Traders Daily

Aug 13, 2026

Aug 12, 2026

Mizuho Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $100 - Moomoo

Aug 12, 2026

Tarsus Pharmaceuticals (TARS) Holds Above $65 Support After Modest Pullback to $68.68Gap Up Stocks - vinanet.vn

Aug 12, 2026

TARS Maintained by Oppenheimer -- Price Target Raised to $100 - GuruFocus

Aug 12, 2026

Oppenheimer Adjusts PT on Tarsus Pharmaceuticals to $100 From $97, Keeps Outperform Rating - marketscreener.com

Aug 12, 2026

Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Raises Target Price to $100 - Moomoo

Aug 12, 2026

Aug 10, 2026

Tarsus Pharmaceuticals (TARS) Surges 4.6% to $67.76, Pressing Against ResistanceChandelier Stop - vinanet.vn

Aug 10, 2026

Aug 09, 2026

Tarsus Pharmaceuticals Signs Agreement to Acquire Alkeus Pharmaceuticals - Global Legal Chronicle

Aug 09, 2026

The Manufacturers Life Insurance Company Cuts Stock Position in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat

Aug 09, 2026